Netherlands Cancer Institute
1 products tracked · names used in filings: Netherlands Cancer Institute
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 14 Sep 2026🇪🇺 EU refusal
Tacquell (Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded): EU marketing authorisation refused
Thu 25 Jun 2026🇪🇺 CHMP negative opinion
Tacquell (Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded): CHMP negative opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Tacquell Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded | Refused |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.